New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 6, 2012
08:08 EDTINFIInfinity Pharmaceuticals sees FY12 revenue $47.1M, consensus $113.91M
Infinity expects FY12 total revenue $47.1M composed of $45.0M for reimbursed R&D services from Mundipharma and $2.1M due to the amortization of deferred revenue. Infinity does not expect to recognize any revenue in future periods from the previous strategic alliance with Purdue and Mundipharma. Infinity expects FY12 operating expenses $125M-$135M revised from an earlier expectation of $135M-$145M. Infinity expects FY12 net loss $35M-$45M. Cash and investments: Infinity expects to end 2012 with a year-end cash and investments balance ranging from $155M-$165M, revised from an earlier expectation of $65M-$75M.
News For INFI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 22, 2015
10:05 EDTINFIHigh option volume stocks
Subscribe for More Information
09:43 EDTINFIActive equity options trading
Active equity options trading according to Track Data: AAPL DG ABX AMZN FXCM LVS FFIV INFI SD
January 12, 2015
08:14 EDTINFIInfinity Pharmaceuticals sees reporting Dynamo data in 2H15
Infinity (INFI) anticipates that it will report top line data from DYNAMO, a Phase 2 study of duvelisib in patients with refractory indolent non-Hodgkin lymphoma, in the second half of 2015 following the completion of patient enrollment in the first half of the year. Infinity also expects to complete enrollment of DUO, a Phase 3 study of duvelisib in patients with relapsed/refractory chronic lymphocytic leukemia, in the second half of 2015. During the year, Infinity expects three company-sponsored clinical studies of duvelisib to be initiated, including the first clinical study of duvelisib in combination with venetoclax . Duvelisib is an investigational oral inhibitor of phosphoinositide-3-kinase -delta and PI3K-gamma being developed jointly with AbbVie (ABBV) in oncology.
08:13 EDTINFIInfinity Pharmaceuticals sees FY15 revenue $105M-$125M, consensus $96.45M
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use